What does MSI high/low mean? Which has a better prognosis in colon cancer?
Carolyn Vachani, RN, MSN, AOCN, OncoLink Nurse Educator, responds:
Tumors are identified as MSI-H (i.e. MSI-high), meaning they are MMR deficient (dMMR), or MSI-stable and MSI-low, meaning they are considered MMR proficient (pMMR). Studies have found MSI-H tumors are associated with a better prognosis and is present in approximately 22% of stage II colon tumors (but only 12% of stage III tumors). Several studies have found that patients with stage II MSI-H tumors not only did not derive any benefit from 5-FU adjuvant therapy, but they actually fared worse if they were treated. This was not seen for stage III MSI-H tumors. MS-stable disease, however, may benefit from 5-FU based treatment. Some experts recommend testing for MSI testing as another tool to determine the need for treatment in stage II disease.
Learn more: http://www.oncolink.org/types/article.cfm?c=5&s=11&ss=84&id=9621
This question and answer was part of the OncoLink Brown Bag Chat Series. View the entire Interpreting Test Results transcript.
Nov 15, 2013 - For patients with Burkitt's lymphoma, a low-intensity treatment consisting of infused etoposide, doxorubicin, and cyclophosphamide with vincristine, prednisone, and rituximab is highly effective, according to a study published in the Nov. 13 issue of the New England Journal of Medicine.
Apr 26, 2012
Apr 5, 2011
Feb 9, 2010
Feb 15, 2010